HMHA1 | Histocompatibility (minor) HA-1 | Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
IDO1 | Indoleamine 2,3-dioxygenase 1 | Cancer-related genes Enzymes Predicted intracellular proteins
| | | | | Tissue enhanced |
IGSF21 | Immunoglobin superfamily, member 21 | Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
IKZF1 | IKAROS family zinc finger 1 (Ikaros) | Cancer-related genes Disease related genes Predicted intracellular proteins Predicted membrane proteins Transcription factors
| | | | | Tissue enhanced |
IKZF3 | IKAROS family zinc finger 3 (Aiolos) | Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
IL2RA | Interleukin 2 receptor, alpha | Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
IL2RB | Interleukin 2 receptor, beta | Cancer-related genes CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
IL2RG | Interleukin 2 receptor, gamma | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
IL4I1 | Interleukin 4 induced 1 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
IL7R | Interleukin 7 receptor | Cancer-related genes CD markers Disease related genes Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ITGA2B | Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) | Cancer-related genes Candidate cardiovascular disease genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ITGAL | Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) | CD markers FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ITGAM | Integrin, alpha M (complement component 3 receptor 3 subunit) | Cancer-related genes CD markers Disease related genes Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ITGAX | Integrin, alpha X (complement component 3 receptor 4 subunit) | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
JAK3 | Janus kinase 3 | Cancer-related genes Cytoskeleton related proteins Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
KAZN | Kazrin, periplakin interacting protein | Predicted intracellular proteins
| | | | | Tissue enhanced |
KIAA0101 | KIAA0101 | Mitochondrial proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
KIAA0226L | KIAA0226-like | Predicted intracellular proteins
| | | | | Tissue enhanced |
KIF18B | Kinesin family member 18B | Predicted intracellular proteins
| | | | | Tissue enhanced |
KIF21B | Kinesin family member 21B | Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
KLRC3 | Killer cell lectin-like receptor subfamily C, member 3 | Predicted membrane proteins
| | | | | Tissue enhanced |
KLRK1 | Killer cell lectin-like receptor subfamily K, member 1 | Cancer-related genes CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
LAG3 | Lymphocyte-activation gene 3 | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LAT | Linker for activation of T cells | Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
LCK | LCK proto-oncogene, Src family tyrosine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
LCN2 | Lipocalin 2 | Candidate cardiovascular disease genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LEF1 | Lymphoid enhancer-binding factor 1 | Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
LRMP | Lymphoid-restricted membrane protein | Cytoskeleton related proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
LTF | Lactotransferrin | Cancer-related genes Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LY86 | Lymphocyte antigen 86 | Predicted secreted proteins
| | | | | Tissue enhanced |
MAP4K1 | Mitogen-activated protein kinase kinase kinase kinase 1 | Enzymes Predicted intracellular proteins
| | | | | Tissue enhanced |
MARCO | Macrophage receptor with collagenous structure | Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
MKI67 | Marker of proliferation Ki-67 | Cancer-related genes Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
MMP9 | Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
MTFR2 | Mitochondrial fission regulator 2 | Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
MYBL2 | V-myb avian myeloblastosis viral oncogene homolog-like 2 | Cancer-related genes Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
MYO1F | Myosin IF | Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
MYO1G | Myosin IG | Predicted intracellular proteins
| | | | | Tissue enhanced |
NCF1 | Neutrophil cytosolic factor 1 | Disease related genes Predicted intracellular proteins
| | | | | Tissue enhanced |
NKG2-E | Uncharacterized protein {ECO:0000313|Ensembl:ENSP00000437563} | Predicted membrane proteins
| | | | | Tissue enhanced |
NOXO1 | NADPH oxidase organizer 1 | FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
NUSAP1 | Nucleolar and spindle associated protein 1 | Predicted intracellular proteins
| | | | | Tissue enhanced |
OASL | 2'-5'-oligoadenylate synthetase-like | Predicted intracellular proteins
| | | | | Tissue enhanced |
ORC1 | Origin recognition complex, subunit 1 | Disease related genes Predicted intracellular proteins
| | | | | Tissue enhanced |
OSBP2 | Oxysterol binding protein 2 | Predicted intracellular proteins
| | | | | Tissue enhanced |
P2RY13 | Purinergic receptor P2Y, G-protein coupled, 13 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
PAX5 | Paired box 5 | Cancer-related genes Disease related genes Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
PDCD1 | Programmed cell death 1 | CD markers Disease related genes Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
PF4V1 | Platelet factor 4 variant 1 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
PITPNM3 | PITPNM family member 3 | Disease related genes Predicted intracellular proteins
| | | | | Tissue enhanced |